Appus:  autoimmune and inflammatory disease preclinical stage drug candidate.

Appus is natural protein/peptide animal tissue extract at preclinical stage of development with a following data:

  • non-clinical safety studies: positive acute toxicity evaluation on rats with 50x time overdosing
  • hypothetical mechanism of action:  IL -10 up regulation by factor x10 and TNF -alpha level downregulation by 40-50% at ex vivo induced human PBMC cells.
  • Indications:
    • over 40% reduction of pathological score at collagen induced mouse model of RA
    • positive, anecdotal observations at MS and ALS volunteers (delivery per os).
    • >90% efficacy at pilot clinical trials at dogs Pyometra treatment.